How Often Should a CER Be Updated Under EU MDR? A Practical Guide

This article examines the MDR requirements for CER maintenance, how CER updates relate to PSUR and PMCF activities, the factors that can influence update frequency, and the circumstances that may prompt an earlier review.

Key Takeaways

• The MDR does not establish a universal CER update schedule based on device classification alone
• Article 61(11) and Annex XIV require clinical evaluation to be maintained continuously throughout the device lifecycle
• For Class III and implantable devices, the PMCF evaluation report and SSCP must be updated at least annually; this does not automatically mean the CER itself must be updated annually
• PSUR update frequencies should not automatically be applied as CER update intervals
• New post-market evidence, literature, device changes, and state-of-the-art developments can all trigger an earlier CER review
• A defensible CER update strategy documents the rationale for the chosen review frequency based on the specific device, its risks, and its clinical evidence base
• CER conclusions must remain aligned with risk management documentation, PMS findings, and PMCF outputs throughout the lifecycle

Table of Contents

1. Direct Answer: How Often Should a CER Be Updated?
2. Why It Matters: CER Maintenance Under EU MDR
3. How It Works: MDR Requirements and Update Triggers
4. Common Mistakes: CER Update Errors to Avoid
5. Best Practices: Building a Defensible CER Update Strategy
6. Comparison Table
7. Checklist
8. Definitions
9. Expert Perspective
10. FAQ
11. References
12. Related Resources
13. Call to Action

Direct Answer: How Often Should a CER Be Updated?

There is no single statutory answer. The EU MDR does not establish a universal annual, biennial, or five-year CER update schedule based solely on device classification. Instead, Article 61 and Annex XIV require clinical evaluation to be maintained throughout the device lifecycle, informed by clinical data from PMCF and post-market surveillance activities.

The right question is not how many years can pass before the CER must be updated. The right question is whether the current clinical evaluation still accurately reflects the device’s clinical evidence, post-market experience, state of the art, and benefit-risk profile.

Update frequency should be documented and justified based on the specific device, its risk profile, the maturity and stability of its clinical evidence base, and the findings generated through ongoing post-market surveillance and PMCF activities.

Why It Matters: CER Maintenance Under EU MDR

What Does the EU MDR Require for CER Updates?

Understanding how often a CER should be updated starts with distinguishing between a fixed document-review schedule and the MDR’s broader requirement for ongoing clinical evaluation.

Article 61(11) of the MDR requires the clinical evaluation and its documentation to be updated throughout the device lifecycle using clinical data obtained from the implementation of the manufacturer’s PMCF plan and Post-Market Surveillance system. The MDR connects clinical evaluation to the evidence generated throughout the device lifecycle and does not establish a single update interval for each device classification. New clinical information should be assessed for its potential impact on the existing clinical evaluation, including safety, performance, clinical benefit, and the benefit-risk determination.

For Class III and implantable devices, Article 61(11) contains an additional requirement relating to the PMCF evaluation report and, where indicated, the Summary of Safety and Clinical Performance (SSCP), which must be updated at least annually with the relevant data. This annual requirement should not automatically be interpreted as a universal statutory requirement to update the CER itself annually.

Annex XIV Part A reinforces this lifecycle approach by requiring manufacturers to plan, continuously conduct, and document clinical evaluation. The manufacturer must establish and update a Clinical Evaluation Plan (CEP) and systematically identify, appraise, and analyse relevant clinical data relating to the device.

Taken together, Article 61 and Annex XIV show that CER maintenance under the MDR extends beyond a predetermined review interval. Manufacturers need a process for continually identifying evidence, assessing its significance, and determining whether the existing clinical evaluation and associated documentation remain adequately supported.

What Determines CER Update Frequency?

Device classification remains important because clinical evidence and post-market oversight should be proportionate to device risk. Class I devices generally include lower-risk products such as certain non-invasive devices, while Class IIa and IIb include progressively higher-risk devices such as certain diagnostic, therapeutic, and invasive devices. Class III includes the highest-risk devices, including many implantable devices such as heart valves and certain cardiovascular implants. The classification alone should not be used as a substitute for assessing the clinical evidence and post-market experience of the individual device.

CER Update Frequency vs PSUR and PMCF Update Frequency

The MDR establishes specific update frequencies for certain post-market documents. These timelines can inform clinical evaluation activities but should not be interpreted as fixed CER update intervals.

Under Article 86 of the MDR, manufacturers of Class IIb and Class III devices are required to update the Periodic Safety Update Report (PSUR) at least annually. For Class IIa devices, the PSUR must be updated when necessary and at least every two years. Class I devices are subject to the Post-Market Surveillance Report requirements under Article 85, with the report updated when necessary.

A PSUR and a CER serve different regulatory purposes. The PSUR summarises and analyses the results and conclusions of post-market surveillance data gathered through the manufacturer’s PMS system. The CER documents the clinical evaluation and assesses the clinical evidence supporting the device’s safety, performance, and clinical benefits.

PMCF introduces another important consideration. Clinical data generated through PMCF contribute to the ongoing clinical evaluation. For Class III and implantable devices, the PMCF evaluation report and, where indicated, the Summary of Safety and Clinical Performance (SSCP) must be updated at least annually with the relevant data.

The timing of PSUR, PMS, and PMCF activities can inform the CER update strategy, but their frequencies should not be treated as interchangeable regulatory requirements. The selected CER review frequency should remain appropriate to the device and its evolving clinical evidence.

How It Works: MDR Requirements and Update Triggers

What Could Trigger an Earlier CER Review?

Manufacturers may establish a planned CER review frequency based on device risk, clinical evidence, post-market activities, and regulatory strategy. New information with the potential to alter the existing conclusions can trigger an earlier reassessment.

New post-market evidence from PMCF results, significant PMS findings, emerging complaint trends, serious incidents, or Field Safety Corrective Actions (FSCAs) may provide new information about the device’s safety, performance, or clinical use. Where these findings challenge the evidence or assumptions in the existing clinical evaluation, their impact should be assessed before the next planned CER review.

New clinical or scientific evidence from published literature may identify previously unrecognised risks, new information about clinical performance, changes in available treatment alternatives, or developments in the accepted state of the art. New literature does not automatically require CER revision; its potential impact on the existing clinical evaluation should first be assessed.

Changes to device design, intended purpose, indications, target population, clinical claims, or other characteristics may affect the applicability of the supporting clinical evidence. New information challenging the use of data from an equivalent device may also require reassessment of whether the existing evidence remains sufficient.

New information affecting identified risks or the overall benefit-risk determination should be considered within the clinical evaluation. The CER should remain consistent with the manufacturer’s risk management documentation and continue to support the device’s clinical claims.

What Should Be Reviewed During a CER Update?

A CER update should reassess the available clinical evidence, including newly published literature and the latest post-market data. The update should determine whether the evidence continues to support the device’s safety, performance, clinical benefits, intended purpose, and overall benefit-risk profile.

A CER update should answer a broader question: does the totality of the current evidence still support the conclusions previously reached? This assessment helps keep the CER aligned with the device’s current clinical evidence.

Maintaining Alignment Across Regulatory Documentation

New evidence identified during CER maintenance may also affect related regulatory documentation. Where the clinical evaluation changes, the manufacturer should consider whether corresponding updates are required to maintain consistency across risk management, PMS, PMCF, clinical claims, and other relevant technical documentation.

MDCG 2020-13 reflects this alignment in the Clinical Evaluation Assessment Report Template, which considers the Clinical Evaluation Plan, clinical evidence, safety and clinical performance, residual risks, PMS and PMCF information, CER conclusions, and consistency with risk management.

Common Mistakes: CER Update Errors to Avoid

Assuming PSUR frequency automatically determines CER frequency

Annual or biennial PSUR reporting cycles should not automatically be applied as CER update intervals. The CER review frequency should be justified according to the device, its risks, and available clinical evidence.

Treating the update as a document revision

Adding newly identified literature or post-market information is not sufficient without assessing its impact on the existing clinical evaluation. The update should determine whether the available evidence continues to support conclusions on safety, performance, clinical benefit, and benefit-risk.

Failing to reassess the state of the art

Clinical practice, alternative treatments, relevant guidelines, and accepted safety or performance benchmarks can change even when the device has not. These developments may change the context in which its clinical evidence is evaluated.

Treating PMCF as separate from clinical evaluation

PMCF findings contribute to the clinical evidence base and should be considered when maintaining the CER.

Allowing regulatory documentation to become inconsistent

CER conclusions should remain aligned with the available evidence and related risk management documentation. New evidence may also affect support for existing clinical claims or the intended purpose.

Following an arbitrary update schedule

Selecting an annual, two-year, or longer interval without documenting why it is appropriate for the device can result in a calendar-driven process that does not adequately account for clinical evidence and risk.

For a full breakdown of how documentation gaps affect regulatory submissions see our article on reasons Clinical Evaluation Reports are rejected.

Best Practices: Building a Defensible CER Update Strategy

Because the MDR does not establish a universal CER update interval, manufacturers should define a device-appropriate strategy based on risk, clinical evidence, post-market experience, and a clear regulatory rationale.

The device risk profile and characteristics provide a practical starting point. Classification, intended purpose, novelty, clinical use, maturity of the available evidence, and known or emerging risks can influence the level of clinical surveillance required. Higher-risk or less established devices may require closer review than mature devices with a stable clinical and post-market history.

The Clinical Evaluation Plan (CEP) should define the approach to clinical evaluation and support a structured review process. Relevant post-market activities and evidence surveillance should be considered when planning CER reviews, including how new literature, state-of-the-art developments, and post-market findings will be identified and assessed.

The review frequency and triggers for earlier reassessment should be documented and justified. Whether the CER is reviewed annually, every two years, or at another interval, the rationale should reflect the device, its risks, available clinical evidence, and post-market experience.

Comparison Table: CER vs PSUR vs PMCF Evaluation Report

Checklist: CER Update Readiness Under EU MDR

Planning and process:

• Clinical Evaluation Plan (CEP) is current and defines the approach to ongoing clinical evaluation
• CER review frequency is documented and justified based on device risk, clinical evidence, and post-market experience
• Triggers for earlier CER review are defined and understood across relevant teams
• Literature surveillance is conducted regularly using a structured and reproducible methodology

Evidence assessment:

• New literature has been identified and assessed for its impact on existing clinical evaluation conclusions
• PMCF findings have been evaluated and reflected in the clinical evidence assessment where relevant
• PMS and PSUR findings have been reviewed for their potential impact on the CER
• State-of-the-art developments have been assessed for their effect on accepted benchmarks and benefit-risk conclusions
• Complaint trends, serious incidents, and FSCAs have been considered within the clinical evaluation

Documentation alignment:

• CER conclusions are consistent with current risk management documentation
• Clinical claims and intended purpose continue to be supported by the available evidence
• Any changes to device design or intended use have been assessed for their impact on clinical evidence sufficiency
• Related regulatory documentation has been updated where CER conclusions have changed
• MDCG 2020-13 alignment has been confirmed across the Clinical Evaluation Assessment Report

Definitions

Clinical Evaluation Report (CER)
The document in which a manufacturer compiles, evaluates, and documents the clinical evidence supporting a medical device’s safety, performance, clinical benefits, and benefit-risk profile. Required under Article 61 and Annex XIV of the EU MDR, the CER must be maintained throughout the device lifecycle.

Clinical Evaluation Plan (CEP)
The document that defines the scope, methodology, and evidence requirements for the clinical evaluation. The CEP must be established and updated throughout the device lifecycle and forms the basis for CER development and maintenance.

Post-Market Clinical Follow-Up (PMCF)
The structured process through which manufacturers actively collect clinical data on their device after market entry. PMCF findings contribute to the ongoing clinical evaluation and must be reflected in CER updates where relevant. For Class III and implantable devices, the PMCF evaluation report must be updated at least annually.

Periodic Safety Update Report (PSUR)
A post-market document required under Article 86 of the EU MDR for Class IIa, IIb, and Class III devices. It summarises and analyses the results of post-market surveillance activities. PSUR update frequencies should not automatically be applied as CER update intervals.

State of the art
The current standard of clinical practice, available treatment alternatives, and accepted safety or performance benchmarks in the relevant clinical field. The state of the art must be assessed as part of clinical evaluation and can change independently of the device itself.

Summary of Safety and Clinical Performance (SSCP)
A publicly available document required for Class III and certain Class IIb implantable devices. For Class III and implantable devices, the SSCP must be updated at least annually with relevant PMCF data, but this requirement does not automatically extend to the CER itself.

Field Safety Corrective Action (FSCA)
An action taken to reduce a risk of death or serious deterioration in health associated with a device’s use. FSCAs are a potential trigger for earlier CER review where they provide new information about safety or benefit-risk.

MDCG 2020-13
A guidance document providing a template for the Clinical Evaluation Assessment Report. It outlines the areas considered during Notified Body assessment of a manufacturer’s clinical evaluation, including consistency with risk management, PMS, and PMCF documentation.

Expert Perspective

The most common failure in CER maintenance is not neglecting to update the document. It is updating the document without genuinely reassessing the evidence. Adding a new literature search and appending the results to an existing CER is not the same as asking whether the totality of available evidence continues to support the clinical conclusions previously reached. Notified Bodies assess the quality of the reassessment, not just the presence of a recently dated document. A CER that was last meaningfully evaluated three years ago but has been formally “updated” annually through literature additions and minor text changes is more likely to generate questions than a CER with a clear, documented rationale for a two-year review cycle supported by a structured evidence assessment.

Frequently Asked Questions

Is there a definitive timeline for updating a CER under the EU MDR?

No. The EU MDR does not establish a universal annual, biennial, or five-year CER update schedule based solely on device class. The review approach should be appropriate to the device, its risks, available clinical evidence, and post-market experience. The review frequency and rationale should be documented within the Clinical Evaluation Plan.

Can a CER need to be reviewed earlier regardless of device class?

Yes. New clinical or post-market information, device changes, or developments affecting the state of the art or benefit-risk determination may prompt reassessment before the next planned review. New information should first be assessed for its relevance and impact; it does not automatically require immediate CER revision. Potential triggers include significant PMS findings, PMCF results, serious incidents, FSCAs, new published literature, and changes to the device or its intended purpose.

Does the annual PMCF update requirement mean the CER must also be updated annually?

Not automatically. For Class III and implantable devices, Article 61(11) requires the PMCF evaluation report and, where indicated, the SSCP to be updated at least annually with relevant data. This requirement should not automatically be interpreted as a statutory requirement to update the CER itself annually. PMCF findings should be assessed for their impact on the clinical evaluation; where they affect existing conclusions, the CER should be updated accordingly.

How does PSUR frequency relate to CER update frequency?

PSUR and CER serve different regulatory purposes. The PSUR summarises and analyses post-market surveillance data; the CER documents the clinical evaluation and assesses clinical evidence. Annual or biennial PSUR reporting cycles should not automatically be applied as CER update intervals. However, PSUR findings can inform the CER update process and may identify evidence that requires reassessment within the clinical evaluation.

Who reviews the CER?

The CER is prepared and maintained by the manufacturer as part of the device’s technical documentation. Where notified body involvement applies, the notified body assesses the manufacturer’s clinical evaluation and supporting clinical evidence. MDCG 2020-13 provides a template for documenting this assessment and considers whether an updated CER corresponds with the latest post-market information.

Who do I submit my CER to?

A CER forms part of the manufacturer’s technical documentation under Article 61(12); it is not routinely submitted to the EU as a standalone document. Where the applicable conformity assessment procedure requires notified body involvement, the CER and supporting clinical evidence form part of the technical documentation assessed by the notified body. The assessment pathway depends on the device classification and applicable conformity assessment procedure.

What are the most common reasons CERs are challenged during Notified Body review?

The most common reasons include insufficient critical appraisal of clinical evidence, misaligned search strategies, inconsistencies between the CER and PMS or PMCF documentation, inadequate state-of-the-art assessment, and an outdated evidence base that does not reflect recent post-market data. For a full breakdown see our article on reasons Clinical Evaluation Reports are rejected.

References

• Regulation (EU) 2017/745 on medical devices (EU MDR) — particularly Article 61, Articles 83 to 86, Annex II, and Annex XIV
• EU MDR Article 61: Clinical Evaluation
• EU MDR Annex XIV: Clinical Evaluation and Post-Market Clinical Follow-Up
• EU MDR Article 86: Periodic Safety Update Report
• MDCG 2020-13: Clinical Evaluation Assessment Report Template

Related Resources

• CER Checklist for EU MDR — A practical framework for pre-submission review of Clinical Evaluation Reports
• Why Clinical Evaluation Reports Are Rejected — Common reasons CERs fail Notified Body review and how to avoid them
• Post-Market Surveillance Under EU MDR — Building a proactive PMS system aligned with EU MDR expectations
• PMCF Surveys Solution — Structured PMCF activities supporting ongoing clinical evidence generation
• EU MDR Literature Review Services — Structured literature surveillance supporting CER maintenance and clinical evaluation
• CER Writing Services — Expert CER writing and clinical evaluation support for medical device manufacturers
• PRISMA and EU MDR Literature Review — Structured literature review methodology supporting CER development and maintenance
• PSUR vs PMSR Under EU MDR — Understanding post-market surveillance reporting requirements

Call to Action

If you are reviewing your Clinical Evaluation Report update strategy, preparing for a Notified Body review, or building a more structured approach to clinical evaluation and post-market surveillance under EU MDR, Citemeds can help. Get in touch to discuss your requirements.